Table 2.
Comparison of low and high TRISE and low and high time interval groups.
| Characteristic | Category |
Low TRISE (n =186) |
High TRISE (n = 187) |
p-value |
Low time interval (n= 192) |
High time interval (n= 200) |
p-value |
|---|---|---|---|---|---|---|---|
| Age (years) | 52.0 (IQR 39.8–66.0) |
59.0 (IQR 49.0–72.0) |
< 0.001 | 53.5 (IQR 44.0–66.0) |
57.0 (IQR 44.0–71.0) |
0.118 | |
| Histology | 0.229 | 0.504 | |||||
| Adeno | 15 (8.1%) | 23 (12.3%) | 22 (11.5%) | 17 (8.5%) | |||
| Squamous | 164 (88.2%) | 153 (81.8%) | 160 (83.3%) | 175 (87.5%) | |||
| Other | 7 (3.8%) | 11 (5.9%) | 10 (5.2%) | 8 (4.0%) | |||
| FIGO stage | 0.093 | 0.513 | |||||
| IB | 27 (14.5%) | 14 (7.5%) | 27 (14.1%) | 17 (8.5%) | |||
| IIA | 6 (3.2%) | 7 (3.7%) | 6 (3.1%) | 9 (4.5%) | |||
| IIB | 68 (36.6%) | 93 (49.7%) | 86 (44.8%) | 87 (43.5%) | |||
| IIIA | 9 (4.8%) | 9 (4.8%) | 10 (5.2%) | 8 (4.0%) | |||
| IIIB | 48 (25.8%) | 47 (25.1%) | 42 (21.9%) | 55 (27.5%) | |||
| IVA | 24 (12.9%) | 14 (7.5%) | 17 (8.9%) | 21 (10.5%) | |||
| IVB | 4 (2.2%) | 3 (1.6%) | 4 (2.1%) | 3 (1.5%) | |||
| Lymphadenopathy | 0.366 | 0.003 | |||||
| Negative | 98 (53.3%) | 86 (46.2%) | 81 (42.2%) | 111 (56.3%) | |||
| Iliac | 61 (33.2%) | 68 (36.6%) | 71 (37.0%) | 66 (33.5%) | |||
| PAO | 25 (13.6%) | 32 (17.2%) | 40 (20.8%) | 20 (10.2%) | |||
| Induction | 0.576 | < 0.001 | |||||
| chemotherapy | No | 140 (75.3%) | 136 (72.7%) | 126 (65.6%) | 166 (83.0%) | ||
| Yes | 46 (24.7%) | 51 (27.3%) | 66 (34.4%) | 34 (17.0%) | |||
| Radiation technique | 0.283 | 0.001 | |||||
| 3DCRT | 146 (78.5%) | 135 (72.2%) | 137 (71.4%) | 163 (81.5%) | |||
| IMRT | 20 (10.8%) | 30 (16.0%) | 23 (12.0%) | 27 (13.5%) | |||
| VMAT | 20 (10.8%) | 22 (11.8%) | 32 (16.7%) | 10 (5.0%) | |||
| Radiation field | 0.148 | 0.978 | |||||
| Pelvic | 138 (74.2%) | 126 (67.4%) | 138 (71.9%) | 144 (72.0%) | |||
| Pelvic + PAO | 48 (25.8%) | 61 (32.6%) | 54 (28.1%) | 56 (28.0%) | |||
| IGBT use | 0.805 | 0.038 | |||||
| No | 154 (82.8%) | 153 (81.8%) | 152 (79.2%) | 174 (87.0%) | |||
| Yes | 32 (17.2%) | 34 (18.2%) | 40 (20.8%) | 26 (13.0%) | |||
| No of treatments | < 0.001 | 0.253 | |||||
| 2 | 7 (3.8%) | 0 (0%) | 3 (1.6%) | 7 (3.5%) | |||
| 3 | 9 (4.8%) | 0 (0%) | 3 (1.6%) | 6 (3.0%) | |||
| 4 | 42 (22.6%) | 5 (2.7%) | 25 (13.0%) | 23 (11.5%) | |||
| 5 | 128 (68.8%) | 182 (97.3%) | 161 (83.9%) | 164 (82.0%) | |||
| Cumulative CEM43T90 | < 0.001 | 0.764 | |||||
| (minutes) | 2.05 (IQR 1.20–3.01) |
5.69 (IQR 3.9–7.64) |
3.55 (IQR 2.03–5.61) |
3.14 (IQR 1.66–6.2) |
|||
| Cumulative TRISE | 0.656 | ||||||
| (degrees Celsius) | 3.44 (IQR 2.93–3.87) |
3.51 (IQR 2.93–3.88) |
|||||
| Time interval (minutes) | 0.347 | ||||||
| 72.5 (IQR 62.0–92.5) |
75.0 (IQR 62.0–95.5) |
Comparison of patients divided over the median TRISE and time interval.